Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.62 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888815 | 0.91 | KCNH2 (0.73) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL2886862 | 0.91 | KCNH2 (0.58) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL2889546 | 0.90 | KCNH2 (0.57) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL2882484 | 0.89 | KCNH2 (0.61) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL13207701 | 0.87 | KCNH2 (0.65) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL13207209 | 0.87 | KCNH2 (0.64) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL2889559 | 0.87 | KCNH2 (0.83) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL2887666 | 0.85 | KCNH2 (0.59) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL2885023 | 0.85 | KCNH2 (0.59) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL2885025 | 0.85 | KCNH2 (0.59) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | claimed |
| EP-1901746-B1 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-02-20 | — | — | EP | claimed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | claimed |
| EP-1901746-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1901746-B1 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| EP-1901746-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | CACNA1G, CACNA1I, CACNA1H | KCNH2 38/4885CACNA1I 2/4885CACNA1H 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.